Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech. JNJ has broken out past $259, while KO just tagged an all-time high near $84.14. That backdrop makes this a real premium-defensive showdown.
Pharma Pipeline Muscle Meets Beverage Brand Muscle
JNJ posted $24.062 billion in revenue, up 9.9% year over year, with adjusted EPS of $2.70. The portfolio mix tells the real story. DARZALEX pulled $3.964 billion (+22.5%) and TREMFYA jumped 68.3% to $1.608 billion, mopping up share from STELARA, which fell 59.7% under biosimilar pressure. CEO Joaquin Duato called it “a strong start to 2026”, and management raised guidance to $100.3B to $101.3B in revenue.
Coca-Cola came in cleaner on the top line. Revenue rose 12.1% to $12.472 billion, with EPS of $0.86 beating by 5.87%. Organic revenue grew 10%, and Zero Sugar volumes climbed 13% across every region. New CEO Henrique Braun credited “staying close to the consumer, executing locally and managing complexity.” Operating margin widened to 35.0% from 32.9%. That is beverage pricing power at its cleanest.
Where the Defensive Bets Really Split
| Lens | JNJ | KO |
| Growth engine | Oncology and MedTech | Zero Sugar and pricing |
| Forward P/E | 23 | 26 |
| Dividend streak | 64 years | 63 years |
| YTD price move | +26.71% | +20.26% |
JNJ carries the messier story. Net income fell 52.4% on $330M in litigation charges, and free cash flow dropped hard. But the pipeline is doing the heavy lifting, with 28 separate billion-dollar platforms and a planned Orthopaedics spin. KO looks pristine, yet volume only grew 3%. Most of the growth is price. That works until it does not.
The Next Catalysts Are Asymmetrical
For JNJ, I am watching TREMFYA and DARZALEX absorb the last of STELARA erosion, plus the December 8 Enterprise Business Review. Polymarket traders currently price a 92% probability of another JNJ earnings beat. For KO, the tests are volume durability outside pricing and the Africa bottling divestiture in H2 2026, which trims a few points of reported revenue.
Why I Lean JNJ For The Next Twelve Months
On the numbers, JNJ screens more attractively here. A 23 forward multiple for double-digit oncology growth and a raised outlook feels underpriced next to KO paying 26 times forward earnings for mid-single-digit organic growth. If you are a strict income investor who wants zero drug-pipeline risk, KO’s 2.53% yield and brand moat still fit. I would only pivot to KO if input costs settle and volumes actually reaccelerate. Until then, JNJ looks like the better risk-reward premium anchor.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks